Quick Answer
Bolt Biotherapeutics, Inc. reported Net Income of -$33.38 million for fiscal year 2025.
Bolt Biotherapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$33.38M | +47.1% |
| 2024 | -$63.12M | +8.8% |
| 2023 | -$69.20M | +21.5% |
| 2022 | -$88.10M | +10.6% |
| 2021 | -$98.59M | -62.3% |
| 2020 | -$60.73M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.14M | +52.9% | +16.6% |
| June 30, 2025 | -$8.56M | +59.6% | +22.5% |
| March 31, 2025 | -$11.04M | -2.1% | +27.3% |
| September 30, 2024 | -$15.18M | +6.6% | +28.4% |
| June 30, 2024 | -$21.20M | -17.4% | -96.1% |
| March 31, 2024 | -$10.81M | +36.3% | +33.5% |
| September 30, 2023 | -$16.26M | +25.3% | +10.0% |
| June 30, 2023 | -$18.06M | +20.3% | -6.3% |
- Bolt Biotherapeutics, Inc. showed an increase of +47.1% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Bolt Biotherapeutics, Inc.’s net income has grown by 45.0% (from -$60.73 million to -$33.38 million).
- The most recent figure is from Bolt Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: